Delcath Systems Inc (DCTH)

[Rapture2020]

So much for the fake news that DCTH does have full enrollment for the FOCUS trial.

All 240 accounted for.

NEW YORK, May 03, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the independent Data Safety Monitoring Board (DSMB) of the Phase 3 FOCUS clinical trial for Patients with Hepatic Dominant Ocular Melanoma has completed another review of safety data for treated patients in the trial. The DSMB has again recommended that the study continue without modification.
The FOCUS Trial is evaluating the efficacy, safety and pharmacokinetics of Melphalan/HDS versus best alternative standard of care in 240 patients with metastatic ocular melanoma (OM).